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Benefit of continuous treatment for responders with newly
diagnosed multiple myeloma in the randomized FIRST trial
NJ Bahlis1, A Corso2, L-O Mugge3, Z-X Shen4, P Desjardins5, A-M Stoppa6, O Decaux7, T de Revel8, M Granell9, G Marit10, H Nahi11,
H Demuynck12, S-Y Huang13, S Basu14, TH Guthrie15, A Ervin-Haynes16, J Marek16, G Chen16 and T Facon17
The phase 3, randomized Frontline Investigation of Revlimid and Dexamethasone Versus Standard Thalidomide (FIRST) trial
investigating lenalidomide plus low-dose dexamethasone until disease progression (Rd continuous) vs melphalan, prednisone and
thalidomide for 12 cycles (MPT) and Rd for 18 cycles (Rd18) in transplant-ineligible patients with newly diagnosed multiple
myeloma (NDMM) showed that Rd continuous prolonged progression-free survival and overall survival compared with MPT.
A subanalysis of the FIRST trial was conducted to determine the benefits of Rd continuous in patients with NDMM based on depth
of response. Patients randomized 1:1:1 to Rd continuous, Rd18 or MPT were divided into subgroups based on best response:
complete response (CR; n= 290), ⩾ very good partial response (VGPR; n= 679), ⩾partial response (PR; n= 1 225) or ⩽ stable disease
(n= 299). Over 13% of patients receiving Rd continuous who achieved ⩾VGPR as best response did so beyond 18 months of
treatment. Rd continuous reduced the risk of progression or death by 67%, 51% and 35% vs MPT in patients with CR, ⩾VGPR and
⩾ PR, respectively. Similarly, Rd continuous reduced the risk of progression or death by 61%, 54% and 38% vs Rd18 in patients with
CR, ⩾ VGPR and ⩾ PR, respectively. In patients with CR, ⩾ VGPR or ⩾ PR, 4-year survival rates in the Rd continuous arm (81.1%,
73.1% or 64.6%, respectively) were higher vs MPT (70.8%, 59.8% or 57.2%, respectively) and similar vs Rd18 (76.5%, 67.7% and
62.5%, respectively). Rd continuous improved efficacy outcomes in all responding patients, including those with CR, compared with
fixed duration treatment.
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INTRODUCTION
For patients with newly diagnosed multiple myeloma (NDMM),
treatment objectives include disease control and extended
survival.1,2 Maintaining response is an important factor for
prolonging survival in patients with multiple myeloma, in addition
to achieving a high quality of response.3,4 Moreover, patients with
relapsed and refractory multiple myeloma are often more frail
because of disease progression or comorbidities and may be
unable to receive aggressive, yet efficacious, salvage therapies,
highlighting the importance of maintaining first remission.5
Current standards of care for patients with NDMM who are
ineligible for stem cell transplant are fixed duration combination
therapy with melphalan, prednisone and thalidomide (MPT)6–8 or
bortezomib, melphalan and prednisone in many parts of the
world.9,10 In addition, the pivotal phase 3, randomized interna-
tional Frontline Investigation of Revlimid and Dexamethasone
Versus Standard Thalidomide (FIRST) trial established lenalidomide
plus dexamethasone (Rd) until disease progression (Rd contin-
uous) as a new standard of care for this patient population.11
Specifically, data from the FIRST trial showed that Rd continuous
significantly improved progression-free survival (PFS) compared
with fixed duration MPT (12 cycles (72 weeks); hazard ratio (HR)
for progression or death = 0.72 (95% confidence interval (CI),
0.61–0.85); Po .001) or Rd for 18 cycles (72 weeks (Rd18);
HR = 0.70 (95% CI, 0.60–0.82); Po .001).11 At the interim overall
survival (OS) analysis, Rd continuous also improved OS compared
with MPT (HR for risk of death = 0.78 (95% CI, 0.64–0.96)). Results
from this trial led to the approval of lenalidomide plus low-dose
dexamethasone for the treatment of previously untreated multiple
myeloma in patients who were ineligible for transplant.12,13
Results from a pooled analysis of the phase 3 MM-009 and
MM-010 studies of lenalidomide plus low-dose dexamethasone in
patients with relapsed and refractory multiple myeloma showed
that patients who continued treatment experienced prolonged OS
compared with those who discontinued treatment before disease
progression.14 Furthermore, another pooled analysis of the same
two trials found that higher quality responses to lenalidomide plus
low-dose dexamethasone were associated with an OS benefit in
patients with relapsed and refractory multiple myeloma.15
However, it is unknown whether continuing Rd therapy until
disease progression results in improved outcomes for patients
with NDMM in all response categories, especially for those who
achieve complete remission. This retrospective post hoc analysis of
the FIRST trial examined subgroups of patients based on best
response achieved to determine the impact of continuing
treatment with Rd on PFS and OS.
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The phase 3, randomized, multicenter, open-label FIRST trial (MM-020) was
conducted at 246 treatment centers in 18 countries in collaboration with
the Intergroupe Francophone du Myélome (IFM 2007-01). Methods for this
study have been previously described.11 Briefly, patients were randomized
1:1:1 by an interactive voice response system to Rd continuous until
disease progression or unacceptable toxicity, Rd18 (72 weeks), or MPT for
12 cycles (72 weeks). Patients were stratified by age, country and
International Staging System stage. In the Rd continuous and Rd18 arms,
lenalidomide was administered 25 mg per day on days 1–21 and
dexamethasone was given 40 mg on days 1, 8, 15 and 22 of a 28-day
cycle. In the MPT arm, patients were administered melphalan 0.25 mg/kg
on days 1–4, prednisone 2 mg/kg on days 1–4 and thalidomide 200 mg
per day in 42-day cycles. Starting dose adjustments of dexamethasone,
thalidomide and melphalan were made based on age, lenalidomide and
melphalan based on level of renal function, and melphalan based on
hematologic status. Thromboprophylaxis with low-dose aspirin, low-
molecular-weight heparin, warfarin or equivalent was mandatory for all
patients.
This study was approved by an institutional review board for each study
site before initiation of any study procedures and was conducted in
accordance with the Declaration of Helsinki and the principles of Good
Clinical Practice (as outlined by the International Conference on
Harmonisation E6 requirements). All patients provided informed consent.
All authors had access to the primary clinical trial data and, with the
sponsor, analyzed and interpreted the data. This trial is registered as
NCT00689936.
Patients
Eligible patients aged ⩾ 65 years or o65 years and ineligible for stem cell
transplant had previously untreated, symptomatic and measurable MM as
defined by International Myeloma Working Group criteria.16 Patients must
have had an Eastern Cooperative Oncology Group performance status
score of 0–2. Patients were excluded if they had received any prior
antimyeloma treatment, with the exceptions of radiotherapy, bispho-
sphonates or short-term steroids. Patients with laboratory abnormalities
including absolute neutrophil count o1.0 × 109/l, untransfused platelet
count o50 × 109/l, or aspartate aminotransferase or alanine aminotrans-
ferase 43.0 × the upper limit of normal; renal failure requiring dialysis;
peripheral neuropathy ⩾grade 2; or a history of malignancies, other than
multiple myeloma, within the last 3 or fewer years were also excluded.
Assessments
The primary endpoint was PFS, defined as time from randomization to the
first documentation of disease progression or death because of any cause.
Secondary endpoints included OS (time from randomization to death
because of any cause), duration of response (time of initial response to
confirmed disease progression), time to response (time from randomiza-
tion to first response), time to second antimyeloma treatment (time from
randomization to the first day the patient received second-line anitmye-
loma treatment) and safety. Response and disease progression data
reported here were investigator assessed using the International Myeloma
Working Group criteria.16 An independent committee monitored efficacy
and safety data throughout the study. Patients were retrospectively
divided into four response subgroups: complete response (CR), ⩾ very
good partial response (VGPR; CR or VGPR), ⩾partial response (PR; CR, VGPR
or PR) and ⩽ stable disease (SD; SD or progressive disease). Patients who
did not have any evaluable response were not included in this analysis.
Landmark analyses of PFS and OS were conducted at 18 months after
randomization for patients who achieved CR or ⩾VGPR. The primary
comparators in the MM-020 trial, and hence this analysis, were Rd
continuous vs MPT, as the study was not powered for the comparisons of
Rd continuous vs Rd18 and Rd18 vs MPT. The purpose of this analysis was
to evaluate the benefit of continuous Rd treatment vs MPT for patients
with deep responses. As the response categories are mutually exclusive
and add up to the total population, each individual response category (CR,
Table 1. Baseline patient characteristics by response subgroups





















































39 (34) 28 (25) 18 (27) 84 (33) 81 (32) 58 (35) 145 (34) 139 (33) 114 (31) 25 (33) 43 (48) 50 (37)
Male,
n (%)
64 (56) 58 (53) 36 (55) 147 (57) 133 (52) 87 (52) 239 (55) 220 (52) 196 (53) 40 (53) 46 (52) 69 (51)
ECOG PS, n (%)
0 38 (33) 32 (29) 17 (26) 84 (33) 77 (30) 46 (28) 130 (30) 135 (32) 109 (30) 21 (28) 21 (24) 38 (28)
1 52 (46) 55 (50) 32 (48) 122 (47) 119 (47) 89 (54) 214 (50) 205 (48) 190 (52) 34 (45) 45 (51) 68 (51)
2 24 (21) 23 (21) 16 (24) 51 (20) 59 (23) 29 (17) 86 (20) 85 (20) 67 (18) 20 (26) 23 (26) 27 (20)
⩾3 0 0 0 1 (0.4) 0 0 1 (o1) 0 0 0 0 0
Missing 0 0 1(2) 0 0 2 (1) 1 (o1) 0 2 (1) 1 (1) 0 1 (1)
ISS stage, n (%)
I/II 78 (68) 69 (63) 43 (65) 160 (62) 155 (61) 91 (55) 263 (60.9) 273 (64.2) 232 (63.0) 49 (64.5) 36 (40.4) 71 (53.0)
III 36 (32) 41 (37) 23 (35) 98 (38) 100 (39) 75 (45) 169 (39.1) 152 (35.8) 136 (37.0) 27 (35.5) 53 (59.6) 63 (47.0)
CrCl (ml/min), n (%)
o30 7 (6) 12 (11) 7 (11) 14 (5) 22 (9) 18 (11) 29 (7) 31 (7) 30 (8) 7 (9) 11 (12) 19 (14)
⩾ 30 to o50 23 (20) 14 (13) 12 (18) 59 (23) 48 (19) 34 (20) 107 (25) 84 (20) 74 (20) 13 (17) 28 (31) 33 (25)
⩾ 50 to o80 59 (52) 57 (52) 18 (27) 121 (47) 119 (47) 63 (38) 193 (45) 205 (48) 157 (43) 36 (47) 35 (39) 51 (38)
⩾80 25 (22) 27 (25) 29 (44) 64 (25) 66 (26) 51 (31) 103 (24) 105 (25) 107 (29) 20 (26) 15 (17) 31 (23)
Cytogenetics, n (%)a
High risk 5 (4) 7 (6) 0 13 (5) 18 (7) 5 (3) 33 (7) 35 (8) 32 (9) 7 (9) 12 (13) 13 (10)
Standard risk 42 (37) 45 (41) 35 (53) 101 (39) 99 (39) 80 (48) 166 (38) 167 (39) 146 (40) 30 (39) 33 (37) 42 (31)
Abbreviations: Cont, continuous; CR, complete response; CrCl, creatinine clearance; ECOG PS, Eastern Cooperative Oncology Group performance status; ISS,
International Staging System; MPT, melphalan, prednisone and thalidomide; PR, partial response; SD, stable disease; VGPR, very good partial response. aHigh
risk includes del(17p), t(14;16) and t(4;14); standard risk includes all patients not categorized as high risk.
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VGPR and PR) should not be analyzed separately; therefore, responses
were classified into three groups (CR, ⩾VGPR and ⩾ PR).
Statistical analysis
All response-evaluable patients were included in the efficacy analyses.
Safety analyses included all response-evaluable patients who received at
least 1 dose of study drug. The medians for time-to-event endpoints are
based on Kaplan–Meier estimates, and the unstratified log-rank test was
used for comparisons of these endpoints. The Cox proportional hazards
model was used to estimate HRs and 95% CIs.
RESULTS
Patients
Patients were grouped according to best response by investigator
assessment using a data cutoff of 3 March 2014, with a median
follow-up of 45.5 months. Of the 1623 patients in the intent-to-
treat population, 1225 (75.5%) achieved ⩾ PR, including 290
(17.9%) with CR and 679 (41.8%) with ⩾VGPR. There were 299
patients (18.4%) with a best response of ⩽ SD (SD or progressive
disease), including 266 (16.4%) with SD and 33 (2.0%) with
progressive disease. An additional 99 patients (6.1%) were not
evaluable for response and consequently were not included in this
analysis. As indicated in the study flow diagram, 91 patients were
still receiving treatment in the Rd continuous arm (see
Supplementary Figure 1, available on the Leukemia website) and
of these patients, 49 were in CR (43.0% of patients with CR), 80
with ⩾VGPR (31.0% of patients with ⩾ VGPR) and 91 with ⩾ PR
(21.1% of patients with ⩾ PR). There were no notable differences
in baseline characteristics across response subgroups or treatment
arms (Table 1).
Responses, time to response and duration of response
The overall response rate in the Rd continuous arm was 80.7% vs
67.3% and 78.6% in the MPT and Rd18 arms, respectively.17 For all
responders, initial responses occurred in a median time of
o2 months (1.0, 1.0 and 1.5 months for patients with CR; 1.1,
1.0 and 1.6 months for patients with ⩾ VGPR; 1.8, 1.8 and
2.8 months for patients with ⩾ PR; Supplementary Table 1) in the
Rd continuous, Rd18 and MPT arms, respectively. Patients with
high-quality response (that is, ⩾ VGPR) as best response tended to
have faster times to initial response across all treatment arms. Of
patients who achieved CR, median time to first CR was 10.4, 8.3
and 11.3 months in the Rd continuous, Rd18 and MPT arms,
respectively. Median time to first VGPR was 5.6, 4.1 and 6.2 months
for patients who achieved VGPR in the Rd continuous, Rd18 and
MPT arms, respectively. Of patients in the Rd continuous arm who
achieved ⩾ VGPR as best response, 88.8% (n= 229) had a PR as
initial response and 13.2% (n= 34) achieved ⩾VGPR beyond
18 months of treatment (Figure 1a). In contrast, 2.7% (n= 7) of
patients who achieved ⩾VGPR as best response with Rd18 did so
beyond 18 months of treatment (Figure 1b).
Duration of response was substantially longer with Rd
continuous vs MPT and Rd18 across all response subgroups,
especially in patients with ⩾VGPR and those with CR (Figure 2). In
particular, in patients achieving CR, responses were sustained by
an additional 19 months or more in patients receiving Rd
continuous vs MPT or Rd18 (median duration of response, 59.1
vs 34.2 or 40.1 months, respectively). A similar magnitude of
improvement with Rd continuous was also observed in patients
achieving ⩾VGPR compared with MPT or Rd18. Responses were
also maintained by an additional 9–10 months in all responders
(⩾ PR) who received Rd continuous treatment compared with
either fixed duration regimen (MPT or Rd18). Subgroup analyses
for duration of response in patients with ⩾VGPR are presented in
Supplementary Figure 2.
Figure 1. Cumulative response by treatment month for patients who achieved VGPR or better as best response. (a) Patients in the Rd
continuous arm. (b) Patients in the Rd18 arm. Percentage shown is for patients achieving VGPR or better in the current month.
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Progression-free survival
Rd continuous treatment prolonged PFS in responding patients
compared with MPT and Rd18, with a reduction in the risk of
progression or death by 35% and 38%, respectively (Figure 3).
This benefit was even more pronounced in patients with higher
quality responses. Patients who achieved CR or ⩾ VGPR had a
67% and 51% reduction in the risk of progression or death with
Rd continuous vs MPT, respectively. Similarly, Rd continuous
reduced the risk of progression or death by 61% and 54% vs
Rd18 in patients with CR and ⩾ VGPR, respectively. Rates of 4-
year PFS were nearly doubled with Rd continuous vs MPT or
Rd18 for those achieving CR (74.8% vs 37.5% or 39.8%,
respectively) and more than doubled in patients achieving
⩾ VGPR (54.7% vs 23.0% or 22.6%, respectively) or ⩾ PR (39.1% vs
14.7% or 15.5%, respectively). A PFS benefit was observed
with higher quality responses within all treatment arms
(Supplementary Figure 3).
To further evaluate continuous treatment with Rd vs fixed
duration treatment with MPT among patients with deep
responses, landmark analyses of PFS were performed at 18 months
for patients with CR or ⩾VGPR. Among the 259 patients who
achieved CR and were evaluable at this time point, median PFS
was 42.0 months with Rd continuous compared with 21.9 months
with MPT (HR= 0.29 (95% CI, 0.17–0.50); Po0.00001). At the
18-month landmark analysis of patients with ⩾VGPR (n= 540),
median PFS was 38.0 months with Rd continuous vs 17.1 months
with MPT (HR= 0.41 (95% CI, 0.30–0.56); Po0.00001).
Overall survival
After a median follow-up of 45.5 months, Rd continuous improved
survival in all subgroups of responders compared with MPT
(Figure 4). Similar to PFS, patients with deeper responses also
showed greater OS benefits with Rd continuous vs MPT, with
reductions in the risk of death of 43%, 42% and 22% in patients
with CR, ⩾ VGPR and ⩾ PR, respectively (Figure 4). Rates of 4-year
survival of 81.1%, 73.1% and 64.6% were observed with Rd
continuous compared with 70.8%, 59.8% and 57.2% with MPT in
patients with CR, ⩾VGPR and ⩾ PR, respectively. No OS benefits
were observed in patients with ⩽ SD. In the Rd18 arm, 4-year
survival rates were 76.5%, 67.7% and 62.5% in patients with CR,
⩾VGPR and ⩾ PR, respectively.
Landmark analyses were performed at 18 months evaluating OS
of patients with CR or ⩾ VGPR. Among the 276 patients who
achieved CR and were evaluable at this time point, median OS was
42.9 months with Rd continuous compared with 40.3 months with
MPT (HR= 0.57 (95% CI, 0.30–1.08); P= 0.082). At the 18-month
landmark analysis of patients with ⩾VGPR (n= 624), median OS
was not reached with Rd continuous vs 37.3 months with MPT
(HR= 0.50 (95% CI, 0.35–0.72); P= 0.00016).
Time to second-line antimyeloma therapy
In line with results showing prolonged PFS, time to second-line
antimyeloma treatment was considerably prolonged in patients
treated with Rd continuous vs MPT or Rd18 across all subgroups of
responding patients (Table 2). Median time to second-line
antimyeloma treatment was extended by 18.5 (HR = 0.28), 23.0
(HR = 0.40) and 17.8 months (HR = 0.64) with Rd continuous
compared with MPT in patients achieving CR, ⩾ VGPR and ⩾ PR,
respectively. Similarly, Rd continuous prolonged time to second-
line antimyeloma therapy by 8.1 (HR = 0.36), 20.8 (HR = 0.45) and
18.0 months (HR = 0.70) compared with Rd18 in patients achieving
CR, ⩾VGPR and ⩾ PR, respectively. Of note, the 258 patients who
achieved ⩾VGPR in the Rd continuous arm had a median time to
second-line antimyeloma therapy of approximately 5 years. Time
to second-line antimyeloma treatment was similar across treat-
ment arms in patients with ⩽ SD.
Figure 2. Kaplan–Meier estimates of duration of response.
(a) Patients who achieved CR. (b) Patients who achieved VGPR or
better. (c) Patients who achieved PR or better.
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Safety
Grade 3/4 treatment-emergent adverse events of interest across
response subgroups are presented in Table 3. The safety profile of
each treatment was generally consistent across response sub-
groups. However, for patients in the Rd continuous and Rd18
arms, lower rates of grade 3/4 neutropenia and anemia were
observed with a higher quality response.
Rates of dose reductions, dose interruptions and discontinua-
tions of lenalidomide because of treatment-emergent adverse
events were generally higher with Rd continuous vs fixed
duration Rd18 treatment in patients with responses of CR,
⩾ VGPR or ⩾ PR. Rates of lenalidomide discontinuation with Rd
continuous were generally comparable with rates of thalidomide
discontinuation with fixed duration MPT across all response
subgroups. In the 271 patients in the Rd continuous arm treated
for ⩾18 months, 10.3% (n= 28), 11.1% (n= 30), 11.4% (n= 31)
and 13.3% (n= 36) of patients were being treated with
lenalidomide without dexamethasone at month 18, 24, 30 and
36, respectively. In these 271 patients, the median durations of
lenalidomide and dexamethasone treatments were 36.5 and
29.8 months, respectively, and the median duration of lenalido-
mide treatment after dexamethasone discontinuation was
16.1 months. In addition, 15.1% (n= 41), 10.3% (n = 28), 8.5%
(n= 23), 5.9% (n= 16) and 4.1% (n= 11) of patients in the Rd
continuous arm treated for ⩾ 18 months were receiving
lenalidomide alone without dexamethasone for at least 12, 18,
24, 30 and 36 months, respectively. Of patients who remained on
treatment in the Rd continuous arm at 1 year (n= 422), 2 years
(n= 276) and 3 years (n= 171), 28.0%, 38.8% and 50.3%,
respectively, were not receiving lenalidomide at their initial
dose within the previous six cycles of treatment.
DISCUSSION
This retrospective post hoc analysis of the FIRST trial, the largest
prospective phase 3 study of transplant-ineligible patients with
Figure 3. Kaplan–Meier estimates of PFS. (a) Patients who achieved CR. (b) Patients who achieved VGPR or better. (c) Patients who achieved PR
or better. (d) Patients who achieved no better than SD. NE indicates not estimable.
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Figure 4. Kaplan–Meier estimates of OS. (a) Patients who achieved CR. (b) Patients who achieved VGPR or better. (c) Patients who achieved PR
or better. (d) Patients who achieved no better than SD.
Table 2. Time to second-line antimyeloma treatment by response subgroups
CR (n=290) ⩾ VGPR (n=679) ⩾ PR (n=1225) ⩽ SD (n= 299)
Median time to second-line antimyeloma treatment, months
Rd continuous 60.7 60.7 49.8 6.9
Rd18 52.6 39.9 31.8 7.9
MPT 42.2 37.7 32.0 7.8
HR (95% CI)
Rd continuous vs MPT 0.28 (0.16–0.49) 0.40 (0.30–0.55) 0.64 (0.53–0.78) 1.26 (0.91–1.74)
Rd continuous vs Rd18 0.36 (0.21–0.62) 0.45 (0.34–0.60) 0.70 (0.58–0.85) 1.10 (0.77–1.57)
Abbreviations: CI, confidence interval; CR, complete response; HR, hazard ratio; MPT, melphalan, prednisone and thalidomide; PR, partial response; SD, stable
disease; VGPR, very good partial response.
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NDMM to date, clearly demonstrates the benefits attained by
continuing treatment with Rd until disease progression in all
responding patients, irrespective of the quality of response.
Greater clinical benefits were seen with Rd continuous in patients
with a higher quality of response, with larger differences in PFS
and OS between Rd continuous and MPT observed in patients
with CR. In all groups of responders (CR, ⩾ VGPR and ⩾ PR), the
rate of 4-year PFS was approximately doubled or more with Rd
continuous compared with MPT or Rd18, reaching almost 75% for
patients with CR compared with 38% or 40%, respectively. An
improvement in OS was also seen with Rd continuous for all
groups of responders, with an increase observed in 4-year survival
compared with MPT. Although the study was not powered for the
comparison of Rd continuous vs Rd18, rates of 4-year survival were
similar with Rd continuous vs Rd18 for all groups of responders.
Notably, 413% of patients with a high-quality response achieved
⩾VGPR after 18 months of treatment with Rd, highlighting the
importance of Rd continuous treatment.
Although it is known that greater depth of response is
associated with improved outcomes in patients with multiple
myeloma, it remains to be determined whether continuing
therapy once complete or high-quality responses are achieved
improves patient outcomes.18–22 This analysis of the FIRST trial
demonstrates that Rd continuous compared with MPT or Rd18
resulted in significantly more durable responses and prolonged
PFS in all response subgroups, including those with CR.
Furthermore, these differences in PFS between Rd continuous
and MPT were preserved in the 18-month landmark analyses of
patients who achieved CR or ⩾VGPR. In the FIRST trial, Rd
continuous treatment induced and maintained durable responses
that were prolonged by 19 months or more in patients with CR or
⩾VGPR compared with MPT and Rd18. Importantly, the superior
durability of high-quality responses, CR or ⩾VGPR, with Rd
continuous compared with MPT resulted in a respective 10.3%
and 13.3% improvement in 4-year survival.
This subanalysis of the FIRST trial is in agreement with the
previous findings in favor of depth of response as a surrogate
marker for survival, and also shows an added benefit of treatment
duration. One retrospective analysis reported that approximately
40% of patients who had achieved CR had relapsed at the time of
analysis, highlighting the need for long-term disease control to
improve outcomes.22 Our results confirm that it is not only
important to achieve a response, but that responses can be
maintained by long-term treatment and, consequently, PFS can be
further improved in patients with deep responses. This subanalysis
demonstrates that continuous treatment significantly benefits all
patients, regardless of best response. In fact, the rate of 4-year PFS
with Rd continuous in all responders ⩾ PR (39.1%) was compar-
able to that in patients with CR treated with MPT (37.5%) or Rd18
(39.8%). This highlights the importance of factors beyond quality
of response for determining outcomes, such as maintaining a
response with continuous treatment. Of note, 91 responding
patients (⩾ PR) were still on Rd continuous treatment at the time
of data cutoff, including 49 patients with CR (which constituted
nearly half the patients who achieved CR with Rd continuous), and
80 patients with ⩾VGPR. There were marginal survival benefits for
responders with Rd continuous vs Rd18; interestingly, the benefits
were more pronounced in patients with CR or ⩾VPGR.
With appropriate dose modifications, continuous treatment
with Rd until disease progression was feasible, resulted in rapid
and sustained disease control, and improved long-term survival
outcomes vs treatment with MPT. These data support the use of
Rd continuous therapy beyond achievement of best response
until disease progression as a standard treatment regimen for
transplant-ineligible patients with NDMM, especially patients who
achieve high-quality responses.
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Century Oncology, speaker’s bureau from BMS, Novartis, BI Pharmaceuticals; AE-H
and JM are employees of and have stock ownership in Celgene; GC reports
employment, stock options and travel expenses for Celgene and TF has received
compensation for leadership, honoraria, advisory/consulting, speaker’s bureau and
travel expenses from Celgene. The remaining authors declare no conflict of interest.
Table 3. Grade 3/4 TEAEs of interest by response groups


























Neutropenia 25 (22) 17 (15) 30 (45) 63 (24) 42 (16) 76 (46) 123 (28) 101 (24) 175 (48) 25 (33) 39 (44) 62 (46)
Anemia 9 (8) 10 (9) 12 (18) 40 (16) 27 (11) 31 (19) 76 (18) 54 (13) 64 (17) 16 (21) 26 (29) 30 (22)
Thrombocytopenia 5 (4) 10 (9) 11 (17) 18 (7) 15 (6) 22 (13) 34 (8) 25 (6) 38 (10) 7 (9) 14 (16) 19 (14)
Nonhematologic
Infections 33 (29) 18 (16) 8 (12) 84 (33) 49 (19) 22 (13) 132 (31) 84 (20) 56 (15) 16 (21) 24 (27) 25 (19)
Cardiac disorders 15 (13) 5 (5) 3 (5) 31 (12) 19 (7) 13 (8) 55 (13) 29 (7) 31 (8) 4 (5) 8 (9) 12 (9)
Cataract 13 (11) 4 (4) 1 (2) 27 (10) 9 (4) 2 (1) 32 (7) 12 (3) 3 (1) 1 (1) 2 (2) 0
Deep vein
thrombosis
6 (5) 6 (5) 0 18 (7) 11 (4) 4 (2) 25 (6) 18 (4) 11 (3) 4 (5) 2 (2) 3 (2)
Peripheral sensory
neuropathy
2 (2) 0 10 (15) 5 (2) 1 (o1) 24 (14) 6 (1) 2 (o1) 42 (11) 0 0 9 (7)
Abbreviations: Cont, continuous; CR, complete response; MPT, melphalan, prednisone and thalidomide; PR, partial response; SD, stable disease; TEAE,
treatment-emergent adverse event; VGPR, very good partial response.
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